Haemonetics Corporation (NYSE:HAE) Receives $75.89 Consensus PT from Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $75.8889.

Several research firms recently issued reports on HAE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Haemonetics in a research report on Wednesday, October 8th. Barrington Research reissued an “outperform” rating and set a $86.00 price target on shares of Haemonetics in a report on Tuesday. Mizuho reduced their price objective on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Citigroup reduced their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. Finally, Robert W. Baird started coverage on Haemonetics in a research note on Thursday, June 26th. They issued an “outperform” rating and a $87.00 price objective for the company.

Haemonetics Stock Performance

HAE stock opened at $51.20 on Friday. The stock has a market capitalization of $2.47 billion, a PE ratio of 15.66, a price-to-earnings-growth ratio of 0.93 and a beta of 0.37. Haemonetics has a 12-month low of $47.31 and a 12-month high of $94.99. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The stock’s 50 day simple moving average is $51.83 and its 200 day simple moving average is $62.55.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to analysts’ expectations of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP increased its stake in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares in the last quarter. UMB Bank n.a. grew its position in shares of Haemonetics by 91.7% during the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 320 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Haemonetics during the second quarter valued at about $64,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.